These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 7032921)
1. CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. Mouridsen HT; Palshof T; Engelsman E; Sylvester R Eur J Cancer (1965); 1980; Suppl 1():119-23. PubMed ID: 7032921 [No Abstract] [Full Text] [Related]
2. [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both]. Clavel B; Cappelaere JP; Guerin J; Klein T; Pommatau E; Berlie J Sem Hop; 1982 Sep; 58(34):1919-23. PubMed ID: 6293073 [TBL] [Abstract][Full Text] [Related]
3. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group. Neoplasma; 1985; 32(3):381-7. PubMed ID: 2862594 [TBL] [Abstract][Full Text] [Related]
4. Alternating cyclical hormonal-cytotoxic combination chemotherapy in postmenopausal patients with breast cancer. An EORTC trial. Heuson JC; Sylvester R; Engelsman E Eur J Cancer (1965); 1980; Suppl 1():113-7. PubMed ID: 7032920 [No Abstract] [Full Text] [Related]
5. Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. Krook JE; Ingle JN; Green SJ; Bowman WD; Everson LK; Windschitl HE; Marschke RF; Laurie JA; Cullinan SA; Pfeifle DM Cancer Treat Rep; 1985 Apr; 69(4):355-61. PubMed ID: 3888386 [TBL] [Abstract][Full Text] [Related]
6. CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women. Salimtschik M; Snel S; Havsteen H; Dombernowsky P; Mouridsen HT Cancer Treat Rep; 1980; 64(4-5):635-7. PubMed ID: 7000346 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer. Mouridsen HT; Palshof T; Brahm M; Rahbek I Cancer Treat Rep; 1977; 61(1):47-50. PubMed ID: 324620 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for stage II breast cancer. Hubay CA; Pearson OH; Marshall JS; Rhodes RS; Debanne SM; Mansour EG; Hermann RE; Jones JC; Flynn WJ; Eckert C; McGuire WL Eur J Cancer (1965); 1980; Suppl 1():189-95. PubMed ID: 7032932 [No Abstract] [Full Text] [Related]
9. The case for adjuvant CMF chemotherapy in breast cancer. Has it been made? Levitt SH; Potish RA Cancer Clin Trials; 1981; 4(4):363-9. PubMed ID: 7032731 [TBL] [Abstract][Full Text] [Related]
10. Current overview of EORTC clinical trials with tamoxifen. Heuson JC Cancer Treat Rep; 1976 Oct; 60(10):1463-6. PubMed ID: 1021227 [TBL] [Abstract][Full Text] [Related]
11. Surgical adjuvant trials in the United States. Rozencweig M; Von Hoff DD; Allegra JC; Muggia FM Eur J Cancer (1965); 1980; Suppl 1():173-7. PubMed ID: 7032929 [No Abstract] [Full Text] [Related]
12. [CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer]. Gottwald G; Szakolczai I Orv Hetil; 1983 Jan; 124(2):79-84. PubMed ID: 6687491 [No Abstract] [Full Text] [Related]
13. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group. Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M; J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087 [TBL] [Abstract][Full Text] [Related]
14. Hormono-chemotherapy versus hormonotherapy followed by chemotherapy in the treatment of disseminated breast cancer. Cavalli F; Alberto P; Jungi F; Brunner K; Martz G Eur J Cancer (1965); 1980; Suppl 1():125-9. PubMed ID: 7032922 [No Abstract] [Full Text] [Related]
15. Combined cytotoxic and endocrine therapy in postmenopausal patients with advanced breast cancer. A randomized EORTC study of CMF vs CMF + tamoxifen. Mouridsen HT; Rose C; Engelsmann E; Sylvester R; Rotmensz N J Steroid Biochem; 1985 Dec; 23(6B):1141-6. PubMed ID: 3912619 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with four drugs for stage 2 breast cancer. Wheeler TK; Edelstyn GA; Bates TS; Brinkley D; Evans RG; Kitchen G; MacRae KD; Nicol NT; Spittle M; Wheeler TK Eur J Cancer (1965); 1980; Suppl 1():161-3. PubMed ID: 7032926 [No Abstract] [Full Text] [Related]
17. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. Johansen J; Overgaard J; Overgaard M Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320 [TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic breast cancer in estrogen receptor positive patients. A randomized trial comparing tamoxifen alone versus tamoxifen plus CMF. Bezwoda WR; Derman D; De Moor NG; Lange M; Levin J Cancer; 1982 Dec; 50(12):2747-50. PubMed ID: 6754067 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women. Mouridsen HT; Salimtschik M; Dombernowsky P; Gelshoj K; Palshof T; Rorth M; Daehnfeldt JL; Rose C Eur J Cancer (1965); 1980; Suppl 1():107-10. PubMed ID: 7032918 [No Abstract] [Full Text] [Related]
20. The tamoxifen trial - a double-blind comparison with stilboestrol in postmenopausal women with advanced breast cancer. Stewart HJ; Forrest AP; Gunn JM; Hamilton T; Langlands AO; McFadyen IJ; Roberts MM Eur J Cancer (1965); 1980; Suppl 1():83-8. PubMed ID: 7032945 [No Abstract] [Full Text] [Related] [Next] [New Search]